摘要
目的探讨普罗布考联合阿托伐他汀对急性冠脉综合征(ACS)患者血清对氧磷酶-1(PON1)及氧化低密度脂蛋白(ox-LDL)水平的影响。方法选取2009年2月至2010年7月确诊ACS的患者,随机分为联合组和他汀组。他汀组给予阿托伐他汀20mg qd;联合组在他汀组用药基础上加用普罗布考0.375mg bid。药物治疗前及随访3个月后分别检测血清PON1和ox-LDL的水平,并监测阿托伐他汀与普罗布考联合应用的不良反应。结果两组患者随访3个月时ox-LDL、PON1水平与治疗前比较差异均有统计学意义(P均<0.05),联合组患者治疗后ox-LDL水平降低幅度大于他汀组,两组患者治疗后ox-LDL水平差异有统计学意义(P<0.05);联合组患者治疗后PON1水平升高幅度大于他汀组,两组治疗后PON1水平差异有统计学意义(P<0.05)。两组不良反应发生率无统计学差异(P>0.05)。结论普罗布考联合阿托伐他汀较单纯使用阿托伐他汀治疗更能有效的升高患者血清PON1及降低Ox-LDL的水平。
Objective To study the influences of probucol combining atorvastatin on levels of serum paraoxonase 1(PON1) and oxidized low-density lipoprotein(ox-LDL) in patients with acute coronary syndrome(ACS).Methods ACS patients diagnosed from Feb.2009 to July,2010 were chosen and randomly divided into combining group and atorvastatin group.The atorvastatin group was treated with atorvastatin(20 mg,once a day) and combining group,with atorvastatin and probucol(0.375 mg,twice a day).The levels of serum PON1 and ox-LDL were detected before the treatment and 3 months after follow-up,and the adverse actions were observed after administration of probucol combining atorvastatin.Results The difference in levels of serum PON1 and ox-LDL had statistical significance between two groups 3 months after follow-up compared with that before the treatment(all P〈0.05).The decrease of level of xo-LDL in combining group was more than that in atorvastatin group,and the difference between two groups had statistical significance(P〈0.05).The increase of level of PON1 in combining group was more than that in atorvastatin group,and the difference had statistical significance(P〈0.05).The incidence of adverse actions had no statistical difference between two groups(P〉0.05).Conclusion The combination of probucol and atorvastatin can increase the level of serum PON1 and decrease the level of serum ox-LDL more effectively compared with atorvastatin used alone.
出处
《中国循证心血管医学杂志》
2012年第2期128-130,共3页
Chinese Journal of Evidence-Based Cardiovascular Medicine